Skip to main content

Table 1 Patient’s characteristic

From: Rapid deployment valve system shortens operative times for aortic valve replacement through right anterior minithoracotomy

Variable All pts.(n = 68) C-Group-(n = 25) R-Group(n = 43) p-value
Age (y) 75.9 (SD 5.7) 74.2 (SD 6.6) 74.1 (SD 6.6) 0.058
BSA (m2) 1.89 (SD 0.17) 1.93 (SD 0.13) 1.86 (SD 0.18) 0.11
Female gender; n (%) 24 (35.3) 8 (32.0) 16 (37.7) >0.5
COPD; n (%) 7 (10.3) 2 (8) 5 (11.6) >0.5
DM; n (%) 26 (38.2) 5 (20) 21 (48.8) 0.022
Creatinine (mg/dl) 1.10 (0.86–1.4) 1.01 (0.7–1.5) 1.20 (1.0–1.4) 0.31
CKD-EPI (ml/min/1,73 m2) 64.5 (SD 21.2) 69.8 (SD 27.0) 61.5 (SD 16.5) 0.18
Chronic AF; n (%) 15 (22.1) 7 (28) 8 (18.6) 0.38
PAVD; n (%) 9 (13.2) 3 (12) 6 (14) >0.5
Stroke; n (%) 4(5.9) 2(8.0) 2(4.7) >0.5
Art.hypertension; n(%) 63(94) 21(87.5) 42(97.7) 0.13
Pul. hypertension; n (%) 24(35.3) 7(28.0) 17(39.5) 0.43
NYHA class III -IV; n (%) 40 (58.8) 14 (56) 26 (60.5) >0.5
LVEF (%) 54 (SD 12.8) 54.2 (SD 14.0) 53.9 (SD 12) 0.25
EuroSCORE II (%) 5.3 (3.7–8.9) 5.0 (3.1–9.1) 5.7 (3.9–9.0) 0.29
Preoperative EOA, cm2 0.78 (SD 0.22) 0.75 (SD 0.25) 0.79 (SD 0.19) >0.5
Preoperative mean aortic valve gradient, mmHG 49.6 (SD 11.6) 48.8 (SD 12.7) 50.1 (SD 10.9) >0.5
  1. Data presented as mean ± standard deviation (SD), median and IQR, or number of observations (n) with proportions (%)
  2. BSA body surface area, COPD Chronic obstructive pulmonary disease, DM diabetes mellitus, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, AF atrial fibrillation, NYHA New York Heart Association Classification, LVEF left ventricular ejection fraction, PAVD peripheral arterial vascular disease; pulmonary hypertension: mean pulmonary pressure > 30 mmHG; EOA effective orifice area